Original Articles
Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease

https://doi.org/10.1006/mcpr.1994.1073Get rights and content

Abstract

Apolipoprotein E (apo E) exists in there allelic, functionally distinct isoforms (apo E2, E3 and E4). Recent work has suggested that apo-E-dependent uptake of lipoproteins may play important roles in the development and maintenance of the nervous system and in the responses to both peripheral and central nervous system injury. If apo-E-mediated transport of lipids were a rate-limiting step in these processes, one might expect that the functional differences between the alleles would be associated with varying predispositions to neurodegenerative and demyelinating diseases. Thus, we looked for an association between particular apo E genotypes and susceptibility to multiple sclerosis and Parkinson's disease. If apo-E-mediated cholesterol uptake were limiting in neuronal growth, one might also expect that apo E2 alleles would slow CNS tumour growth. Accordingly, apo E genotypes were investigated in individuals with sporadic vestibular schwannomas and neurofibromatosis type 2 (NF-2). No significant alteration in the apo E allele distributions was observed in any of these conditions, nor did the apo E genotypes correlate with disease severity. However, we confirmed the previous findings of an over-representation of tha apo E4 allele in autopsy-diagnosed late-onset Alzheimer's disease patients. In addition, our data supported the recent observations that apo E2 may be associated with a protective effect for late-onset Alzheimer's disease. These contrasting risks associated with the apo E2 and E4 alleles strengthen the suggestions that this gene is directly involved in the pathogenesis of Alzheimer's disease.

References (0)

Cited by (70)

  • Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects

    2012, Gene
    Citation Excerpt :

    In addition, two publications were excluded for poor quality and six for insufficient data for calculation of an OR and 95% CI. Therefore, 20 studies were included in the final meta-analysis (Al-Shammri et al., 2005; Ballerini et al., 2000; Carlin et al., 2000; Cocco et al., 2005; Ferri et al., 1999; Gaillard et al., 1998; Høgh et al., 2000; Koutsis et al., 2007; Losonczi et al., 2010; Mehta et al., 2003; Mustafina et al., 2008; Niino et al., 2003; Pinholt et al., 2005; Pirttilä et al., 2000; Ramsaransing et al., 2005; Rubinsztein, 1994; Savettieri et al., 2003; Weatherby et al., 2000; Zakrzewska-Pniewska et al., 2004; Zwemmer et al., 2004), which contained 4080 MS cases and 2897 controls. Table 1 shows the studies identified and their main characteristics.

View all citing articles on Scopus
View full text